Bio-Rad diabetes testing is now connected to FlexLab TLA
The D-100 System connection will provide high volume laboratories improved operational efficiencies to meet the growing worldwide demand for diabetes testing.
Inpeco S.A. and Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced their partnership to connect the Inpeco FlexLabTM track for clinical laboratory automation and the D-100 System, to provide high-volume laboratories improved operational efficiencies in meet the growing worldwide demand for diabetes testing.
Inpeco designs, develops, and manufactures customized TLA solutions that are modular, open, scalable, and fast. Their solutions offer labs automation and traceability from, collection to results improving their diagnostic workflow.
Bio-Rad brings over 40 years of expertise in diabetes testing to the D-100 System, which aids in the diagnosis and monitoring of diabetes. The D-100 features Smart HPLC designed to meet the quality and productivity demands of high-volume labs.
Bio-Rad’s onboard Advisor software automatically reviews results.
“A distinctive feature of our FlexLab TLA solution is its open connectivity,” said Gigi Minola, Inpeco Vice President. “An open system connection gives customers the freedom to choose the instruments they prefer to use for their complete lab automation. We are thrilled to meet our customers’ needs by connecting Bio-Rad’s D-100 instrument to our TLA solution.”
“We are pleased to partner with Inpeco to connect the D-100 System to the Inpeco FlexLab automated track system,” said John Hertia, Bio-Rad President, Clinical Diagnostics Group. “With Inpeco’s solution, we can provide our customers the benefits of our D-100 instrument along with the workflow efficiencies of total laboratory automation.”